6A3A Stock Overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Autolus Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.94 |
| 52 Week High | US$7.10 |
| 52 Week Low | US$1.52 |
| Beta | 1.93 |
| 1 Month Change | -31.48% |
| 3 Month Change | -27.04% |
| 1 Year Change | 152.56% |
| 3 Year Change | -18.26% |
| 5 Year Change | -83.16% |
| Change since IPO | -80.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6A3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.1% | -0.2% | 0.5% |
| 1Y | 152.6% | -22.8% | 1.3% |
Return vs Industry: 6A3A exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: 6A3A exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| 6A3A volatility | |
|---|---|
| 6A3A Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6A3A's share price has been volatile over the past 3 months.
Volatility Over Time: 6A3A's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 467 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Autolus Therapeutics plc Fundamentals Summary
| 6A3A fundamental statistics | |
|---|---|
| Market cap | €1.04b |
| Earnings (TTM) | -€194.25m |
| Revenue (TTM) | €1.58m |
639.0x
P/S Ratio-5.2x
P/E RatioIs 6A3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6A3A income statement (TTM) | |
|---|---|
| Revenue | US$1.70m |
| Cost of Revenue | US$130.48m |
| Gross Profit | -US$128.78m |
| Other Expenses | US$79.60m |
| Earnings | -US$208.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.78 |
| Gross Margin | -7,584.39% |
| Net Profit Margin | -12,272.26% |
| Debt/Equity Ratio | 153.3% |
How did 6A3A perform over the long term?
See historical performance and comparison